-

10:49:53 AM

KNTE Stock News

KNTE - Kinnate Biopharma Inc

05/12/22 4:05 PM

Nasdaq : KNTE

earningslow float

Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates

Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma First patient dosed in

RHEA-AI

neutral

04/18/22 8:00 AM

Nasdaq : KNTE

clinical triallow float

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the

RHEA-AI

neutral

04/08/22 4:30 PM

Nasdaq : KNTE

low float

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical

RHEA-AI

neutral

03/28/22 4:05 PM

Nasdaq : KNTE

earningslow float

Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates

Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mutant melanoma expected in

RHEA-AI

neutral

03/08/22 6:00 PM

Nasdaq : KNTE

low float

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and

RHEA-AI

neutral

03/07/22 6:00 AM

Nasdaq : KNTE

low float

Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a

RHEA-AI

neutral

02/28/22 4:05 PM

Nasdaq : KNTE

conferenceslow float

Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its

RHEA-AI

neutral

02/14/22 8:00 AM

Nasdaq : KNTE

low float

Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the

RHEA-AI

neutral

02/07/22 4:05 PM

Nasdaq : KNTE

conferenceslow float

Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its

RHEA-AI

neutral

01/19/22 4:05 PM

Nasdaq : KNTE

conferencesclinical triallow float

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next

KNTE Data

IndustryPharmaceutical Preparation Manufacturing
Websitekinnate.com
CeoNima Farzan
Security nameKinnate Biopharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees84

About Kinnate Biopharma Inc

kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california.